Prognostic implication of expression of Angiopoietin-2 in acute myeloid leukemia

Leukemia Research

Volumn 32, Issue 6, 2008, Pages 843-844

  Fiedler, Walter ^a   Schuch, Gunter ^a   Loges, Sonja ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

AML; Angiogensis; Angiopoietin; Prognosis; VEGF

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; VASCULOTROPIN A; VASCULOTROPIN C;

ACUTE GRANULOCYTIC LEUKEMIA; CELL PROLIFERATION; EDITORIAL; HUMAN; IMMUNOHISTOLOGY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANGIOPOIETIN-2; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS;

EID: 40949140082     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.10.014     Document Type: Editorial

References (12)

1. Hussong J.W., Rodgers G.M., and Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95 1 (2000) 309-313
2. Schaefer C, Krause M, Joscheck C, Fuhrhop I, Schroeder M, Algenstaedt P, et al. Time course dependent microvascular alterations in a model of myeloic leukemia in vivo. Leukemia; in press.
3. Fiedler W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M., et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89 6 (1997) 1870-1875
4. Muller A., Lange K., Gaiser T., Hofmann M., Bartels H., Feller A.C., et al. Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. Leuk Res 26 2 (2002) 163-168
5. Schuch G., Oliveira-Ferrer L., Loges S., Laack E., Bokemeyer C., Hossfeld D.K., et al. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia 19 8 (2005) 1312-1317
6. Hou H.-A., Chou W.-C., Lin L.-I., Tang J.-L., Tseng M.-H., Huang C.-F., et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk. Res. 32 (2008) 904-912
7. Loges S., Heil G., Bruweleit M., Schoder V., Butzal M., Fischer U., et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 23 6 (2005) 1109-1117
8. Schliemann C., Bieker R., Padro T., Kessler T., Hintelmann H., Buchner T., et al. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 91 9 (2006) 1203-1211
9. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 5322 (1997) 55-60
10. Lobov I.B., Brooks P.C., and Lang R.A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99 17 (2002) 11205-11210
11. Etoh T., Inoue H., Tanaka S., Barnard G.F., Kitano S., and Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 61 5 (2001) 2145-2153
12. Tanaka F., Ishikawa S., Yanagihara K., Miyahara R., Kawano Y., Li M., et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 62 23 (2002) 7124-7129